Cargando…
Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria
Chronic urticaria (CU) is a debilitating skin disease affecting around 1% of the population. CU can be subdivided into chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Different pathophysiological mechanisms have been proposed to play a role in the development of CU, and...
Autores principales: | Pedersen, Nadja Højgaard, Sørensen, Jennifer Astrup, Ghazanfar, Misbah Noshela, Zhang, Ditte Georgina, Vestergaard, Christian, Thomsen, Simon Francis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10379579/ https://www.ncbi.nlm.nih.gov/pubmed/37511088 http://dx.doi.org/10.3390/ijms241411328 |
Ejemplares similares
-
Occurrence and risk factors of mental disorders in patients with chronic urticaria
por: Ghazanfar, Misbah Noshela, et al.
Publicado: (2023) -
Risk of comorbidities in patients diagnosed with chronic urticaria: A nationwide registry-study
por: Ghazanfar, Misbah Noshela, et al.
Publicado: (2020) -
The impact of home treatment and self-administration of omalizumab on chronic urticaria
por: Wiuff, Anne Christine, et al.
Publicado: (2022) -
Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies
por: Ghazanfar, Misbah Nasheela, et al.
Publicado: (2015) -
Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three‐month prospective study
por: Ghazanfar, Misbah Noshela, et al.
Publicado: (2022)